Korea Arlico Pharm

At a glance

Korea Arlico Pharm filed 35 disclosures in the last 12 months, including 5 5% holder, 3 insider and 1 issuance. The most recent key filing was on Oct 15: President's holding rose by 17 sh (new report).

Revenue for 2025 was ₩201B, up 5.7% on 2024. Operating margin was 0.5% against -2.7% a year earlier. Debt was 120% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩95.2B and operating loss of ₩6.3B.

The 2025 annual report lists 228 employees with an average tenure of 5.1 years and average pay of ₩53M, #1562 of 2,191 listed companies by average pay. Its 5 directors and auditors were paid ₩160.3M each on average. It paid ₩75 per common share in cash dividends, against ₩75 a year earlier (+0%). 이항구 and related parties held 39.05% at year end.

Of 5 recent 5%+ holder reports, 1 raised and 3 cut a stake; the largest stake reported was 39.44% on Dec 15.

From the 2025 annual report

Staff: 228 (136 men, 92 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩12.1B. Directors and auditors: 5, paid ₩801.6M in total.

Dividends (common shares)

Largest shareholder

이항구 holds 34.39%; with 8 related parties the group holds 39.05% of common shares at year end (from 39.77% at the start of the year).

Individuals paid ₩500M or more

Auditor: 삼일회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports